GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Proto Script Pharmaceutical Corp (OTCPK:PSCR) » Definitions » Sloan Ratio %

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Sloan Ratio % : 0.00% (As of Sep. 2017)


View and export this data going back to 2011. Start your Free Trial

What is Proto Script Pharmaceutical Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Proto Script Pharmaceutical's Sloan Ratio for the quarter that ended in Sep. 2017 was 0.00%.

As of Sep. 2017, Proto Script Pharmaceutical has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Proto Script Pharmaceutical Sloan Ratio % Historical Data

The historical data trend for Proto Script Pharmaceutical's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proto Script Pharmaceutical Sloan Ratio % Chart

Proto Script Pharmaceutical Annual Data
Trend May12 May13 May14 May15 May16
Sloan Ratio %
- 2.13 - - -

Proto Script Pharmaceutical Quarterly Data
Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Sep16 Dec16 Mar17 Jun17 Sep17
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Proto Script Pharmaceutical's Sloan Ratio %

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proto Script Pharmaceutical's Sloan Ratio % Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's Sloan Ratio % falls into.



Proto Script Pharmaceutical Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Proto Script Pharmaceutical's Sloan Ratio for the fiscal year that ended in May. 2016 is calculated as

Sloan Ratio=(Net Income (A: May. 2016 )-Cash Flow from Operations (A: May. 2016 )
-Cash Flow from Investing (A: May. 2016 ))/Total Assets (A: May. 2016 )
=(-0.033--0.038
-0)/0.012
=41.67%

Proto Script Pharmaceutical's Sloan Ratio for the quarter that ended in Sep. 2017 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2017 )
=(-8.387--0.303
--0.022)/0.235
=-3,430.64%

Proto Script Pharmaceutical's Net Income for the trailing twelve months (TTM) ended in Sep. 2017 was -7.264 (Dec. 2016 ) + -0.506 (Mar. 2017 ) + -0.333 (Jun. 2017 ) + -0.284 (Sep. 2017 ) = $-8.39 Mil.
Proto Script Pharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2017 was 0.041 (Dec. 2016 ) + -0.215 (Mar. 2017 ) + -0.105 (Jun. 2017 ) + -0.024 (Sep. 2017 ) = $-0.30 Mil.
Proto Script Pharmaceutical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2017 was 0 (Dec. 2016 ) + -0.009 (Mar. 2017 ) + -0.012 (Jun. 2017 ) + -0.001 (Sep. 2017 ) = $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proto Script Pharmaceutical  (OTCPK:PSCR) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2017, Proto Script Pharmaceutical has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Proto Script Pharmaceutical Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Headlines

No Headlines